A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease
J
Jared Brosch, MD
Primary Investigator
Enrolling By Invitation
50-100 years
All
Phase
2/3
2 Locations
Brief description of study
A Phase II/III randomized, double-blind, placebo-controlled, cognitive
endpoint, multicenter study of potential disease modifying therapies in
individuals at risk for and with dominantly inherited Alzheimer’s disease.
endpoint, multicenter study of potential disease modifying therapies in
individuals at risk for and with dominantly inherited Alzheimer’s disease.
Detailed description of study
To assess the safety, tolerability, biomarker and cognitive efficacy of
investigational products in subjects who are known to have an Alzheimer’s
disease-causing mutation by determining if treatment with the study drug
slows the rate of progression of cognitive impairment and improves
disease-related biomarkers.
investigational products in subjects who are known to have an Alzheimer’s
disease-causing mutation by determining if treatment with the study drug
slows the rate of progression of cognitive impairment and improves
disease-related biomarkers.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: alzheimers,alzheimer's
-
Age: Between 50 Years - 100 Years
-
Gender: All
Eligibility Criteria
Subjects who are either known to have a mutation causing Alzheimer’s
disease OR who do not know their gene status but are “at-risk” for a
dominantly inherited Alzheimer’s disease (DIAD) mutation AND who are
either 1) cognitively normal and are between 15 years younger (-15) to 10
years older (+10) than their expected age at symptom onset or 2) have mild
symptoms of dementia (CDR 0.5 or 1) and are within 10 years of the onset of
symptoms of dementia.
disease OR who do not know their gene status but are “at-risk” for a
dominantly inherited Alzheimer’s disease (DIAD) mutation AND who are
either 1) cognitively normal and are between 15 years younger (-15) to 10
years older (+10) than their expected age at symptom onset or 2) have mild
symptoms of dementia (CDR 0.5 or 1) and are within 10 years of the onset of
symptoms of dementia.
Exclusion Criteria
Updated on
01 Aug 2024.
Study ID: 1903197307
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
